Denali Therapeutics (DNLI)
(Real Time Quote from BATS)
$14.81 USD
-0.75 (-4.82%)
Updated Apr 25, 2024 01:21 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DNLI 14.81 -0.75(-4.82%)
Will DNLI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNLI
Why Denali Therapeutics (DNLI) Stock Might be a Great Pick
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
Denali's (DNLI) Pipeline Progresses Despite Stiff Competition
Other News for DNLI
First Week of DNLI December 20th Options Trading
GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
Denali Therapeutics price target lowered by $38 at UBS, here's why
Denali Therapeutics files to sell 29.29M shares of common stock for holders